Treatment of orbital myositis with adalimumab (humira)

Journal of Rheumatology

Volumn 32, Issue 7, 2005, Pages 1374-1375

  Adams, Alexa B ^a   Kazim, Michael ^c   Lehman, Thomas J A ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c Department of Opthalmology

Author keywords

Adalimumab; Orbital myositis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G1 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CASE REPORT; DIPLOPIA; EYE PAIN; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYOSITIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; VISUAL ACUITY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; GRANULOMA, PLASMA CELL, ORBITAL; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22244474584     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002;15:121-6.
2. Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology 1997;104:402-8.
3. Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001;85:1220-4.
4. Nakatani-Enomoto S, Aizawa H, Koyama S, Haga T, Takahashi J, Kikuchi K. A patient of recurrent orbital myositis with good response to high-dose intravenous immunoglobulin therapy [Japanese]. Rinsho Shinkeigaku 2002;42:154-7.
5. Wilson MW, Shergy WJ, Haik BG. Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthal Plast Reconstr Surg 2004;20:381-3.
6. Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004;138:925-30.
7. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7.
8. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etancercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40.
9. Van de Putte LBA, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumor necrosis factor-alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168-77.
10. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24.
11. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development. Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.